Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The efficacy and safety of venetoclax and azacitidine combined with granulocyte-colony stimulating factor in the treatment of Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJuan ChenZHZiyi HaoXZXingxia Zhang

Discussion

Loading...

Member takes

Overview

Retrospective analysis demonstrates improved complete response rates with venetoclax and azacitidine in acute myeloid leukemia treatment, suggesting better outcomes for patients.

Key Points

  • Complete response rate was 88% in patients given the venetoclax regimen compared to 62.5% in idarubicin patients, indicating significant efficacy.
  • Overall response rates were 100% in the venetoclax group versus 93.7% in patients receiving idarubicin, showing notable effectiveness of the treatment.
  • Assessment involved 40 newly diagnosed acute myeloid leukemia patients treated with either azacitidine-venetoclax-G-CSF or idarubicin-cytarabine regimens between 2022 and 2023.
  • Results highlight the potential for venetoclax-azacitidine-G-CSF combinations to enhance treatment efficacy, especially for elderly patients.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d343https://doi.org/10.1182/blood-2025-6970
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of G-CSF in combination with venetoclax and azacitidine (VAG) in treatment of patients with higher-risk Myelodysplastic Syndromes (MDS)2025
  2. 2Venetoclax-azacitidine in combination with chidamide and CAG versus daunorubicin and cytarabine in newly diagnosed AML2025
  3. 3Efficacy and safety of azacitidine, venetoclax combined with gha priming regimen in the treatment of adult refractory and relapsed acute myeloid leukemia: A prospective single-arm multicenter study2025
  4. 4Safety and efficacy of venetoclax plus CAG (cytarabine, aclarubicin, G-CSF) regimen in patients with relapsed or refractory Acute Myeloid Leukemia: A prospective single-arm phase II study2025
  5. 5[Clinical Efficacy of CAG Regimen Combined with Venetoclax, Chidamide, and Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia].2025